Apoptosis
Apoptosis(凋亡)
FKBP (FK506-binding protein) is one of two major immunophilins and most of FKBP family members bind FK506 and show peptidylprolyl cis/trans isomerase (PPIase) activity. Small size FKBP family members contain only FK506-binding domain, while FKBPs with large molecular weights possess extra domains such as tetratricopeptide repeat domains, calmodulin binding and transmembrane motifs. FKBPs are involved in several biochemical processes including protein folding, receptor signaling, protein trafficking and transcription. FKBP family proteins play important functional roles in the T-cell activation, when complexed with their ligands.
FK506-binding proteins 1a and 1b (FKBP1a/1b) are immunophilin proteins that bind the immunosuppressant agent FK506 and AY 22989. FKBP12 is a ubiquitous abundant protein that acts as a receptor for FK506, binds tightly to intracellular calcium release channels and to the transforming growth factor β (TGF-β) type I receptor.
Apoptosis 相关产品(777)
- GC74486LexatumumabCAS: 845816-02-6纯度: >96.00%
Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。
- GC74501AdebrelimabCAS: 2247114-85-6纯度: >97.00%
Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。
- GC74614Eftozanermin alfaCAS: 1820660-69-2纯度: >95.00%
Eftozanermin alfa(ABBV-621)是第二代肿瘤坏死因子相关凋亡诱导配体受体(TRAIL-R)激动剂。
- GC74620Zilovertamab vedotin纯度: >98.00%
Zilovertamab vedotin(VLS-101)是一种新型抗体-药物偶联物,其包含人源化单克隆抗体齐洛他单抗和抗微管细胞毒素单体韦多汀。
- GC74684Topoisomerase II inhibitor 14CAS: 305343-00-4纯度: >99.00%
Topoisomerase II inhibitor 14(化合物2f)是拓扑异构酶II的强效抑制剂,具有抗癌活性。
- GC74733Methoxyamine-d3 HydrochlorideCAS: 110220-55-8纯度: >99.00%
Methoxyamine-d3 Hydrochloride (O-Metldroxylamine-d3)是氘标记的甲氧基胺氯。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC74486 | Lexatumumab | 845816-02-6 | >96.00% | |
Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。 | ||||
| GC74501 | Adebrelimab | 2247114-85-6 | >97.00% | |
Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。 | ||||
| GC74515 | Benufutamab | 2109730-69-8 | >98.00% | |
Benufutamab(GEN1029)是一种死亡受体5(DR5)特异性激动抗体。 | ||||
| GC74538 | Sotevtamab | 2411526-47-9 | >99.00% | |
Sotevtamab (16B5)是一种人源IgG2抗聚簇素单克隆抗体(mAb)。 | ||||
| GC74572 | Lilotomab | 1453362-55-4 | >98.00% | |
Lilotomab(0-40µg/mL;12 d)降低DOHH2和Ramos细胞的克隆性存活。 | ||||
| GC74585 | Obexelimab | 1690307-05-1 | >95.00% | |
Obexelimab(XmAb5871)是一种人源化抗CD19抗体。 | ||||
| GC74614 | Eftozanermin alfa | 1820660-69-2 | >95.00% | |
Eftozanermin alfa(ABBV-621)是第二代肿瘤坏死因子相关凋亡诱导配体受体(TRAIL-R)激动剂。 | ||||
| GC74620 | Zilovertamab vedotin | - | >98.00% | |
Zilovertamab vedotin(VLS-101)是一种新型抗体-药物偶联物,其包含人源化单克隆抗体齐洛他单抗和抗微管细胞毒素单体韦多汀。 | ||||
| GC74630 | TI17 | 1005178-02-8 | >97.00% | |
TI17是甲状腺激素受体相互作用蛋白Trip13的抑制剂,具有抗癌活性。 | ||||
| GC74668 | 3-Methoxy-9H-Carbazole | 18992-85-3 | >99.00% | |
3-Methoxy-9H-Carbazole诱导caspase-3活性和细胞产生活性氧。 | ||||
| GC74684 | Topoisomerase II inhibitor 14 | 305343-00-4 | >99.00% | |
Topoisomerase II inhibitor 14(化合物2f)是拓扑异构酶II的强效抑制剂,具有抗癌活性。 | ||||
| GC74721 | Geraniol-d6 (Major) | 1660976-93-1 | >95.00% | |
Geraniol-d6 (Major)是氘代标记的Geraniol Major。 | ||||
| GC74733 | Methoxyamine-d3 Hydrochloride | 110220-55-8 | >99.00% | |
Methoxyamine-d3 Hydrochloride (O-Metldroxylamine-d3)是氘标记的甲氧基胺氯。 | ||||
| GC90076 | HA-14-1 | 927635-64-1 | >95.00% | |
一种Bcl-2抑制剂 | ||||
| GC90483 | Magainin 1 (trifluoroacetate salt) | - | >95.00% | |
一种抗微生物阳离子肽。 | ||||
| GC90489 | AC 187 (trifluoroacetate salt) | - | >95.00% | |
一种钙降素和淀粉样蛋白受体的拮抗剂。 | ||||
| GC90582 | Perfluorooctanesulfonic Acid | 1763-23-1 | >95.00% / >98.00% | |
一种全氟烷基物质 | ||||
| GC90889 | 5-(3'-Hydroxyphenyl)-γ-Valerolactone | 21618-91-7 | >95.00% | |
多种多酚的代谢产物。 | ||||
| GC91096 | S-72 | 2446799-14-8 | >98.00% | |
一种微管聚合抑制剂。 | ||||
| GC91162 | Glucosamine Cholesterol | 1257309-90-2 | >95.00% | |
一种基于葡萄糖胺的脂质共轭物 | ||||
| GC91176 | AOH1996 | 2089314-64-5 | >99.00% | |
一种PCNA抑制剂 | ||||
| GC91228 | SSE1806 | - | >95.00% | |
一种微管不稳定剂 | ||||
| GC91297 | Cholesterol-Doxorubicin | - | >95.00% | |
一种阿霉素的前药形式。 | ||||
| GC91360 | NM-3 | 181427-78-1 | >98.00% | |
NM-3是一种合成异香豆素,可以抑制血管生成。 | ||||
